Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 18/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 18/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.84 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.84 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.66 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4471403 | 1.00 | PIK3CB (0.84) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4528584 | 0.93 | PIK3CB (0.73) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15582985 | 0.92 | PIK3CD (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL15583160 | 0.92 | PIK3CD (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4520743 | 0.90 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4525170 | 0.89 | PIK3CB (0.85) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2950985 | 0.89 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2957383 | 0.88 | PIK3CB (0.74) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4528903 | 0.88 | PIK3CB (0.68) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL4533014 | 0.86 | PIK3CB (0.71) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | claimed |
| EP-2057147-A1 | PYRIMIDINE DERIVATIVES | Astra Zeneca AB (SE) | 2009-05-13 | — | — | EP | claimed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-2057147-A1 | PYRIMIDINE DERIVATIVES | Astra Zeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | TYMP, DPYD, TYMS | PIK3CB 1101/4885PIK3CD 959/4885PIK3CA 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.